Kamada

Kamada KMDA Stock

$8.16   0.616525%
Add to favorites
Market Cap
$471.09M
LOW - HIGH [24H]
$8.05 - $8.22
VOLUME [24H]
$74.67K
P/E Ratio
21.47
Earnings per share
$0.38
ISIN
IL0010941198
Price   Prediction

Kamada Price Chart

Sorry, that's all we've gotfor now...

Kamada (KMDA) stock price today is 8.16 USD on Tech Market Large (+0.62% on the day). Updated .

Kamada KMDA Financial and Trading Overview

Kamada stock price 8.16 USD
Previous Close 8.09 USD
Open 8.18 USD
Bid 5.86 USD x 200
Ask 10.47 USD x 200
Day's Range 8.08 - 8.25 USD
52 Week Range 6.6 - 9.35 USD
Volume 116.21K USD
Avg. Volume 132.02K USD
Market Cap 468.21M USD
Beta (5Y Monthly) 0.199
PE Ratio (TTM) 21.342104
EPS (TTM) 0.38 USD
Forward Dividend & Yield 0.17 (2.10%)
Ex-Dividend Date November 19, 2026
1y Target Est 13.75 USD

KMDA Valuation Measures

Enterprise Value 399.25M USD
Trailing P/E 21.342104
Forward P/E 13.9827585
PEG Ratio (5 yr expected) 0.64
Price/Sales (ttm) 2.378216
Price/Book (mrq) 1.7247978
Enterprise Value/Revenue 2.028
Enterprise Value/EBITDA 9.03

Trading Information

Kamada Stock Price History

Beta (5Y Monthly) 0.199
52-Week Change 18.27%
S&P500 52-Week Change 13.32%
52 Week High 9.35 USD
52 Week Low 6.6 USD
50-Day Moving Average 8.05 USD
200-Day Moving Average 7.99 USD

KMDA Share Statistics

Avg. Volume (3 month) 132.02K USD
Avg. Daily Volume (10-Days) 164.56K USD
Shares Outstanding 57.73M
Float 32.72M
Short Ratio 2.22
% Held by Insiders 7.11%
% Held by Institutions 49.35%
Shares Short 165.78K
Short % of Float 0.53%
Short % of Shares Outstanding 0.28%

Dividends & Splits

Trailing Annual Dividend Rate 0.56
Trailing Annual Dividend Yield 6.92%
5 Year Average Dividend Yield N/A
Payout Ratio 0.65790004
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 12.67%
Operating Margin (ttm) 15.43%
Gross Margin 41.59%
EBITDA Margin 22.45%

Management Effectiveness

Return on Assets (ttm) 4.99%
Return on Equity (ttm) 9.34%

Income Statement

Revenue (ttm) 196.87M USD
Revenue Per Share (ttm) 3.4 USD
Quarterly Revenue Growth (yoy) 10.69%
Gross Profit (ttm) 81.89M USD
EBITDA 44.22M USD
Net Income Avi to Common (ttm) 24.95M USD
Diluted EPS (ttm) 0.38
Quarterly Earnings Growth (yoy) 50.89%

Balance Sheet

Total Cash (mrq) 75.32M USD
Total Cash Per Share (mrq) 1.32 USD
Total Debt (mrq) 11.72M USD
Total Debt/Equity (mrq) 4.37 USD
Current Ratio (mrq) 4.167
Book Value Per Share (mrq) 4.702

Cash Flow Statement

Operating Cash Flow (ttm) 45.21M USD
Levered Free Cash Flow (ttm) 22.89M USD

Profile of Kamada

Country United States
State N/A
City Rehovot
Address 2 Holzman Street
ZIP 7670402
Phone 972 8 940 6472
Website https://www.kamada.com
Industry Drug Manufacturers - Specialty & Generic
Sector(s) Healthcare
Full Time Employees 462

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Q&A For Kamada Stock

What is a current KMDA stock price?

Kamada KMDA stock price today per share is 8.16 USD.

How to purchase Kamada stock?

You can buy KMDA shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Kamada?

The stock symbol or ticker of Kamada is KMDA.

Which industry does the Kamada company belong to?

The Kamada industry is Drug Manufacturers - Specialty & Generic.

How many shares does Kamada have in circulation?

The max supply of Kamada shares is 57.73M.

What is Kamada Price to Earnings Ratio (PE Ratio)?

Kamada PE Ratio is 21.47368400 now.

What was Kamada earnings per share over the trailing 12 months (TTM)?

Kamada EPS is 0.38 USD over the trailing 12 months.

Which sector does the Kamada company belong to?

The Kamada sector is Healthcare.

Kamada KMDA included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 24328.38 USD —
-0.74
8.59B USD — 23989.09 USD — 24547.66 USD — — 8.59B USD —
us US Tech Global Select Market Com NQGS US 11984.26 USD —
-0.73
— — 11815.78 USD — 12090.12 USD — — — —
us US Tech Biotechnology NBI US 7017.81 USD —
-0.71
— — 6949.3 USD — 7058.02 USD — — — —
us US Tech Health Care IXHC US 1332.89 USD —
-0.73
— — 1323.81 USD — 1342.94 USD — — — —
us US Tech Composite Total Return XCMP US 30064.18 USD —
-0.74
— — 29644.9 USD — 30335.16 USD — — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
$2.17T
Total marketcap
$71.18B
Total volume
BTC 58.98%   •   ETH 10.04%
Dominance
Select currency